NIFTY NINE IN NINETY NINE PLUS ONE Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Non-Tech : NIFTY NINE IN NINETY NINE PLUS ONE

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Arthur Radley who wrote (161)	1/18/1999 8:35:00 PM
From: Scott H. Davis	Read Replies (1) of 613

Curious, nobody on this thread seems to be mentioning MLNM or VICL concerning the gene discussing here. (more on that later) What I really planned on posting was a "Wierd Al" style lyric "Where have all the biotech analysts gone? Long time consolidating. Where have all the analysts gone, long large cap fascination ago..." I just scanned the YAHOO research entries for a basket of stocks I follow or semi-follow and one trend leaps out - the shrinking # of analysts covering these companies. CTIC, GERN< ONXX, TRIBY, XOMA all report 0 analysts now. ISIP now only 2, VICL 4. Both had six last year. IMNR went from a 1.8 to a 1.3 on the Zacks rating system this week. New coverage or upgrade? Hardly. The analyst with the hold dropped coverage. Maybe we should re-label this thread "Bull Headed Swimming Upstream" Seriously, I appreciate the analyis done here by some. I'll start contributing more on my picks soon. Scott

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next